|
|
 |
|
|
Bone replacement material is used for tumorectomy or as a substitute
for bone parts lost through injury.
Our substitute bone product is unique in that it becomes an integral part of human bone,
whereas existing artificial bone products remain as foreign matter in the human body for
a long time after being implanted.
The diseased bone is filled with ultra-pure β-TCP bone substitute, which is gradually
absorbed into existing bone as the base for new bone.
In the past, artificial bone has sometimes been avoided altogether due to the potentially
negative impact on the patient's body over an extended period of time. Instead, autologous
bones taken from the patient, or autologous bones mixed with artificial bones, were used.
In contrast, our product requires a minimum or no autologous bone transplant. |
|
 |
|
|
| Molecular formula |
|
Ca3(PO4)2 |
| Molecular weight |
|
310.18 |
| Generic name |
|
β-tricalcium phosphate |
| Appearance, properties |
|
off-white,
highly porous material |
| Porosity |
|
approx. 75% |
| Pore size |
|
100 - 400 µm |
| Product form |
|
block / granule/ circular cylinder |
|
|
|
|
| 1970s |
|
The R&D division of Olympus Optical Co., Ltd. (currently Olympus
Corporation) recognized the development of bone replacement materials as a new business
opportunity in the aging society and commenced research. |
| Early 1980s |
|
Launched joint research with the Government Industrial Research Institute,
Nagoya (currently National Institute of Advanced Industrial Science and Technology (AIST)). |
| 1990-1995 |
|
Conducted clinical tests at the Jikei University School of Medicine and
Nippon Medical School. |
| April 1995 |
|
The block type product was approved as a clinical device under the Pharmaceutical
Law. |
| April 1999 |
|
Launched sales of block-type bone replacement materials. |
| May 2000 |
|
Launched sales of granule-type bone replacement materials. |
|
|
|
